130 related articles for article (PubMed ID: 15615459)
41. Role of treatment intensification in infants with acute lymphoblastic leukemia: results of two consecutive AIEOP studies.
Biondi A; Rizzari C; Valsecchi MG; De Lorenzo P; Aricò M; Basso G; Locatelli F; Lo Nigro L; De Rossi G; Masera G
Haematologica; 2006 Apr; 91(4):534-7. PubMed ID: 16537119
[TBL] [Abstract][Full Text] [Related]
42. The analysis of correlations between drug resistance and clinical/laboratory measures found in a group of children with all treated by ALL-BFM 90 protocol.
Mihal V; Hajduch M; Noskova V; Janostakova A; Safarova M; Orel M; Kouzmina G; Stary J; Blazek B; Pospisilova D
Bull Cancer; 2004 Apr; 91(4):E80-9. PubMed ID: 15562558
[TBL] [Abstract][Full Text] [Related]
43. Reinduction therapy in 297 children with acute lymphoblastic leukemia in first bone marrow relapse: a Pediatric Oncology Group Study.
Buchanan GR; Rivera GK; Boyett JM; Chauvenet AR; Crist WM; Vietti TJ
Blood; 1988 Oct; 72(4):1286-92. PubMed ID: 3167209
[TBL] [Abstract][Full Text] [Related]
44. Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy.
Aricò M; Valsecchi MG; Rizzari C; Barisone E; Biondi A; Casale F; Locatelli F; Lo Nigro L; Luciani M; Messina C; Micalizzi C; Parasole R; Pession A; Santoro N; Testi AM; Silvestri D; Basso G; Masera G; Conter V
J Clin Oncol; 2008 Jan; 26(2):283-9. PubMed ID: 18182669
[TBL] [Abstract][Full Text] [Related]
45. Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: a Children's Cancer Group Study.
Heath JA; Steinherz PG; Altman A; Sather H; Jhanwar S; Halpern S; Pieters R; Shah N; Steinherz L; Tannous R; Terry W; Trigg ME;
J Clin Oncol; 2003 Apr; 21(8):1612-7. PubMed ID: 12697887
[TBL] [Abstract][Full Text] [Related]
46. Precursor B-cell lymphoblastic lymphoma in childhood and adolescence: clinical features, treatment, and results in trials NHL-BFM 86 and 90.
Neth O; Seidemann K; Jansen P; Mann G; Tiemann M; Ludwig WD; Riehm H; Reiter A
Med Pediatr Oncol; 2000 Jul; 35(1):20-7. PubMed ID: 10881003
[TBL] [Abstract][Full Text] [Related]
47. PTEN abnormalities predict poor outcome in children with T-cell acute lymphoblastic leukemia treated according to ALL IC-BFM protocols.
Szarzyńska-Zawadzka B; Kunz JB; Sędek Ł; Kosmalska M; Zdon K; Biecek P; Bandapalli OR; Kraszewska-Hamilton M; Jaksik R; Drobna M; Kowalczyk JR; Szczepański T; Van Vlierberghe P; Kulozik AE; Witt M; Dawidowska M
Am J Hematol; 2019 Apr; 94(4):E93-E96. PubMed ID: 30614545
[No Abstract] [Full Text] [Related]
48. [The prospects for children with acute lymphoblastic leukemia of being cured has increased in the Czech Republic in the 21st century to 90% - outcome of the ALL-IC BFM 2002 trial].
Zdráhalová K; Štěrba J; Domanský J; Blažek B; Ptoszková H; Mihál V; Novák Z; Hak J; Procházková D; Černá Z; Timr P; Jabali Y; Sedláček P; Smíšek P; Zemanová Z; Jarošová M; Houdková A; Mejstříková E; Hrušák O; Zuna J; Janotová I; Trka J; Starý J
Cas Lek Cesk; 2015; 154(2):79-89. PubMed ID: 25994910
[TBL] [Abstract][Full Text] [Related]
49. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
[TBL] [Abstract][Full Text] [Related]
50. Prognostic factors in adolescent and adult patients with acute lymphoblastic leukemia with two protocols of chemotherapy: a cross-sectional study.
Pinheiro Junior ED; Pracchia LF; Beitler de Mauriño B; Martinez GA; Dorlhiac-Llacer PE; Medina AB; Velloso ED
Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):e7-e14. PubMed ID: 25130688
[TBL] [Abstract][Full Text] [Related]
51. Visualization of Vertebral Body Deformities in Childhood by MRI in a Boy with ALL.
Zhang XD; Madjidyar J; Peters S
Rofo; 2019 Aug; 191(8):752-753. PubMed ID: 30900230
[No Abstract] [Full Text] [Related]
52. The Impact of Socioeconomic Factors on the Outcome of Childhood Acute Lymphoblastic Leukemia (ALL) Treatment in a Low/Middle Income Country (LMIC).
Jabeen K; Ashraf MS; Iftikhar S; Belgaumi AF
J Pediatr Hematol Oncol; 2016 Nov; 38(8):587-596. PubMed ID: 27467375
[TBL] [Abstract][Full Text] [Related]
53. Treatment of B-cell malignancies in children with a modified BFM-NHL 90 protocol in Argentina.
Chantada G; Casak S; Alderete D; Zubizarreta P; Gallo G; Muriel FS
Med Pediatr Oncol; 2003 Nov; 41(5):488-90. PubMed ID: 14515400
[No Abstract] [Full Text] [Related]
54. Experience with four consecutive BFM-based protocols for treatment of childhood with non-promyelocytic acute myeloblastic leukemia in Argentina.
Felice MS; Rossi JG; Alonso CN; Gallego MS; Eberle SE; Alfaro EM; Guitter MR; Bernasconi AR; Rubio PL; Coccé MC; Zubizarreta PA
Leuk Lymphoma; 2016 Sep; 57(9):2090-9. PubMed ID: 26734812
[TBL] [Abstract][Full Text] [Related]
55. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G
J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699
[TBL] [Abstract][Full Text] [Related]
56. COVID-19 reinfection in two children with cancer.
Yadav SP; Wadhwa T; Thakkar D; Kapoor R; Rastogi N; Sarma S
Pediatr Hematol Oncol; 2021 May; 38(4):403-405. PubMed ID: 33625290
[No Abstract] [Full Text] [Related]
57. Prognostic relevance of dic(9;20)(p11;q13) in childhood B-cell precursor acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing an intensive induction and post-induction consolidation therapy.
Pichler H; Möricke A; Mann G; Teigler-Schlegel A; Niggli F; Nebral K; König M; Inthal A; Krehan D; Dworzak MN; Janousek D; Harbott J; Schrappe M; Gadner H; Strehl S; Haas OA; Panzer-Grümayer R; Attarbaschi A;
Br J Haematol; 2010 Apr; 149(1):93-100. PubMed ID: 20067563
[TBL] [Abstract][Full Text] [Related]
58. Acute lymphoblastic leukemia in a developing country: preliminary results of a nonrandomized clinical trial in El Salvador.
Bonilla M; Moreno N; Marina N; deReyes G; Shurtleff SA; Downing JR; Behm FG; Harrison PL; Ribeiro RC; Peña O; Crist WM; Antillon FG
J Pediatr Hematol Oncol; 2000; 22(6):495-501. PubMed ID: 11132215
[TBL] [Abstract][Full Text] [Related]
59. Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.
Tzortzatou-Stathopoulou F; Papadopoulou AL; Moschovi M; Botsonis A; Tsangaris GT
J Pediatr Hematol Oncol; 2001 Dec; 23(9):591-7. PubMed ID: 11902303
[TBL] [Abstract][Full Text] [Related]
60. [Outcomes of modified NHL-BFM-90 protocol for children and adolescents with lymphoblastic lymphoma].
Sun X; Zhen Z; Zhu J; Wang J; Lu S; Xia Y; Sun F; Chen Y; Zhang F; Cai R; Li P; Guo X
Zhonghua Xue Ye Xue Za Zhi; 2014 Dec; 35(12):1083-9. PubMed ID: 25543702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
